Compare Herbalife Nutrition Ltd (HLF) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Herbalife Nutrition Ltd vs Neurocrine Biosciences Inc — how do they compare? Herbalife Nutrition Ltd trades at $13.03 (market cap $1.34B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 10.7× Herbalife Nutrition Ltd's market cap, and Herbalife Nutrition Ltd is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and Neurocrine Biosciences Inc for 23 Days on average.
| HLF | NBIX | |
|---|---|---|
Market Cap | $1.34B | $14.36B |
Volume | 1,589,457 | 1,237,180 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $185.50 |
52-Week Low | $7.75 | $123.10 |
Typical Hold Time | 43 Days | 23 Days |
Enterprise Value | $3.18B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Herbalife (HLF) trades at $12.82, up 1.34% on the day, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 EPS of $0.51, missing the $0.536 estimate, but Q1 2026 beat expectations. Revenue for 2025 was $5.04 billion with a net income margin of 4.53%. Recent news includes a $250 million share repurchase program and a planned CEO transition effective October 31, 2026.
HLF presents a mixed outlook; its low P/E of 8.22 and P/S of 0.26 suggest undervaluation, but negative shareholder equity and high debt pose risks. Analyst consensus is bullish with a $19.00 price target, implying significant upside, though earnings misses and leadership changes warrant caution for investors seeking stability.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
